Fractioned Dose Regimen of Sunitinib for Patients with Gastrointestinal Stromal Tumor: A Pharmacokinetic and Treatment Efficacy Study()

AIM: Sunitinib has shown benefit in patients with imatinib (IM)–resistant gastrointestinal stromal tumor (GIST). However, its advantages are somewhat diminished because of associated toxicities. Herein, we clarify the efficacy and safety of fractioned dose regimen of sunitinib by a pharmacokinetic a...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yen-Yang, Yeh, Chun-Nan, Cheng, Chi-Tung, Wu, Chao-En, Chiang, Kun-Chun, Chen, Tsung-Wen, Wang, Chih-Chi, Chen, Jen-Shi, Yeh, Ta-Sen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2014
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225693/
https://www.ncbi.nlm.nih.gov/pubmed/25389456
http://dx.doi.org/10.1016/j.tranon.2014.08.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225693/
https://www.ncbi.nlm.nih.gov/pubmed/25389456
http://dx.doi.org/10.1016/j.tranon.2014.08.004

Ejemplares similares